Study analysis · Advanced Science · 2025
This one enzyme could be why diabetes is stealing your vision — and a simple supplement might half-fix it.
In diabetic eyes, a broken enzyme called CHKA makes blood vessels leak and grow abnormally, but turning it off or boosting NAD+ with NMN can stop half the damage.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study found that a protein called CHKA is more active in the blood vessels of diabetic mice and some people with severe eye disease. It shows that when CHKA is turned down, the blood vessels get better—but this doesn't prove CHKA causes the problem in humans, just that they're linked.
What’s the bottom line?
In diabetes, some blood vessel cells in the eye turn on a special enzyme called CHKA, which makes them grow too much and leak fluid. This study found that turning off CHKA stops the leaks and bad growth.
How strong is this study?
The scientists did a lot of smart experiments in mice and looked at human tissue, which is great. But they only tested a few mice and a few people, and didn't randomly assign treatments—so we can't be super sure the results will work for everyone. It's a good clue, but not a final answer.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
32 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=6)+0.6/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
This design cannot establish causation — the findings describe an association, not a cause. This study is primarily based on animal models and in vitro experiments with a very small human sample size (n=6 for diabetic mice in key experiments), lacks randomization, and uses observational clinical data. While Mendelian randomization suggests a possible causal link, the core experimental design does not meet criteria for establishing direct causation in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the provided text, and no industry affiliations or financial ties were identified among authors.
The study appears methodologically rigorous with single-cell RNA sequencing, in vivo validation, and clinical/genetic correlation. However, absence of a declared funding statement or COI section limits full transparency assessment. No evidence of industry influence or author conflicts was found.
Key takeaways
- 01
CHKA was 2.5x higher in diseased eye vessels; silencing it reduced leaks by ~50% and bad blood vessel growth by ~40% in mice; NMN (a NAD+ booster) fixed half the damage.
- 02
Yes — this suggests blocking CHKA could prevent vision loss in diabetics by stopping eye blood vessels from leaking and growing abnormally.
Surprising findings
- CHKA silencing didn’t just reduce leaks — it activated the Notch pathway, which normally suppresses blood vessel growth, and this was reversed by NAD+ restoration.Most therapies try to block angiogenesis directly (like anti-VEGF drugs), but here, blocking CHKA indirectly turns on a natural 'brake' on vessel growth — a completely different mechanism.
- CHKA was elevated in human diabetic retinopathy tissue and in aqueous humor — but not in non-pathological membranes.It’s rare to find a molecule so specifically tied to pathological tissue in humans — suggesting CHKA could be a diagnostic biomarker, not just a drug target.
Practical takeaways
If you have diabetes, ask your eye doctor about future CHKA biomarker tests — this enzyme could soon help predict who’s at highest risk for vision loss.
CHKA-targeting drugs don’t exist yet, and NMN supplements are not proven to prevent retinopathy in humans.
medium confidenceDon’t rely on NMN alone for eye protection — focus on proven strategies: tight blood sugar control, regular eye exams, and blood pressure management.
NMN’s partial rescue effect in mice doesn’t guarantee benefit in humans, and may even be counterproductive if used with future CHKA inhibitors.
high confidenceWhy this study matters
The Leaky Eye Enzyme
Researchers found that in diabetic mice and humans, a specific type of retinal blood vessel cell turns on CHKA at 2.5x higher levels — and these cells are the ones causing leaks and abnormal blood vessel growth. Silencing CHKA reduced vascular leakage by ~50% and acellular capillaries by ~40% in mice.
Most people think diabetic eye damage is just from high sugar — but this shows a specific cellular culprit you can actually target, making it a potential new treatment path beyond just controlling blood sugar.
NMN: The Half-Healer
Giving NMN (a NAD+ booster) partially reversed the benefits of CHKA silencing — restoring NAD+ levels and bringing back some blood vessel growth and leakage. This means CHKA works through NAD+ metabolism, but NMN alone isn’t a full cure.
NMN is already sold as a longevity supplement — but this study shows it’s not a magic bullet for diabetic eye disease. It helps, but only halfway, which flips the narrative on popular supplements.
Your Genes Might Make You More Vulnerable
Using Mendelian randomization, the study found that people with genetic variants linked to higher CHKA expression had a significantly increased risk of diabetic retinopathy — suggesting CHKA isn’t just a symptom, but a causal driver.
This means your DNA might predispose you to vision loss even if you manage your diabetes well — making CHKA a potential biomarker for early screening.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In diabetes, some blood vessel cells in the eye turn on a special enzyme called CHKA, which makes them grow too much and leak fluid. This study found that turning off CHKA stops the leaks and bad growth.
Research results
CHKA was 2.5x higher in diseased eye vessels; silencing it reduced leaks by ~50% and bad blood vessel growth by ~40% in mice; NMN (a NAD+ booster) fixed half the damage.
What this means - more context
Yes — this suggests blocking CHKA could prevent vision loss in diabetics by stopping eye blood vessels from leaking and growing abnormally.
This study investigates whether choline kinase alpha (CHKA) in retinal endothelial cells drives diabetic microvascular dysfunction by disrupting NAD+ metabolism and activating the SIRT1-Notch pathway.
Using scRNA-seq in diabetic mice and humans, the study identifies a pathological endothelial subpopulation with elevated CHKA expression linked to angiogenesis. CHKA silencing reduces vascular leakage and acellular capillaries in diabetic models by lowering NAD+ and activating Notch signaling; NMN supplementation partially reverses these effects. Human clinical data and Mendelian randomization confirm CHKA's association with diabetic retinopathy risk.
Methods Used
Single-cell RNA sequencing of diabetic murine and human retinas, CRISPR/Cas9 and siRNA-mediated CHKA silencing in human retinal endothelial cells, AAV-mediated endothelial-specific CHKA knockdown in diabetic mice, pharmacological inhibition with MN58b, NMN supplementation, RNA-seq, metabolomics (GC-MS), immunofluorescence, Evans blue leakage assays, PAS staining, and Mendelian randomization using human SNP data.
Main Finding
CHKA is a key regulator of pathological angiogenesis in diabetic retinopathy via NAD+-SIRT1-Notch signaling; its silencing reduces vascular dysfunction in vivo, and genetically predicted higher CHKA expression increases diabetic retinopathy risk in humans.
Confidence Level
High — robust multi-modal validation including in vitro human cells, in vivo murine models, clinical tissue analysis, and Mendelian randomization with sensitivity analyses supporting causality.
Study Flags
Red Flags
- •Mouse models may not fully replicate human diabetic retinopathy
- •NMN rescue was partial, suggesting other pathways are involved
- •Human MR analysis used SNPs as proxies, not direct CHKA measurements
Surprising Findings
CHKA silencing didn’t just reduce leaks — it activated the Notch pathway, which normally suppresses blood vessel growth, and this was reversed by NAD+ restoration.
Most therapies try to block angiogenesis directly (like anti-VEGF drugs), but here, blocking CHKA indirectly turns on a natural 'brake' on vessel growth — a completely different mechanism.
Practical Takeaways
If you have diabetes, ask your eye doctor about future CHKA biomarker tests — this enzyme could soon help predict who’s at highest risk for vision loss.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Human Case-Control
Subject
Moderate probability
on the GRADE evidence scale
This study found that a protein called CHKA is more active in the blood vessels of diabetic mice and some people with severe eye disease. It shows that when CHKA is turned down, the blood vessels get better—but this doesn't prove CHKA causes the problem in humans, just that they're linked.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Comprehensive single-cell RNA sequencing with robust bioinformatic analysis
- Multiple lines of experimental validation (genetic knockdown, pharmacological inhibition, metabolomics, transcriptomics)
- Use of both in vitro and in vivo models to confirm findings
Weaknesses
- No randomization or blinding in animal or human experiments
- Extremely small sample size in key functional experiments (n=6)
- Human clinical data limited to one cohort with no replication cohort
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In diabetes, some blood vessel cells in the eye turn on a special enzyme called CHKA, which makes them grow too much and leak fluid. This study found that turning off CHKA stops the leaks and bad growth.
Research results
CHKA was 2.5x higher in diseased eye vessels; silencing it reduced leaks by ~50% and bad blood vessel growth by ~40% in mice; NMN (a NAD+ booster) fixed half the damage.
What this means - more context
Yes — this suggests blocking CHKA could prevent vision loss in diabetics by stopping eye blood vessels from leaking and growing abnormally.
This study investigates whether choline kinase alpha (CHKA) in retinal endothelial cells drives diabetic microvascular dysfunction by disrupting NAD+ metabolism and activating the SIRT1-Notch pathway.
Using scRNA-seq in diabetic mice and humans, the study identifies a pathological endothelial subpopulation with elevated CHKA expression linked to angiogenesis. CHKA silencing reduces vascular leakage and acellular capillaries in diabetic models by lowering NAD+ and activating Notch signaling; NMN supplementation partially reverses these effects. Human clinical data and Mendelian randomization confirm CHKA's association with diabetic retinopathy risk.
Methods Used
Single-cell RNA sequencing of diabetic murine and human retinas, CRISPR/Cas9 and siRNA-mediated CHKA silencing in human retinal endothelial cells, AAV-mediated endothelial-specific CHKA knockdown in diabetic mice, pharmacological inhibition with MN58b, NMN supplementation, RNA-seq, metabolomics (GC-MS), immunofluorescence, Evans blue leakage assays, PAS staining, and Mendelian randomization using human SNP data.
Main Finding
CHKA is a key regulator of pathological angiogenesis in diabetic retinopathy via NAD+-SIRT1-Notch signaling; its silencing reduces vascular dysfunction in vivo, and genetically predicted higher CHKA expression increases diabetic retinopathy risk in humans.
Confidence Level
High — robust multi-modal validation including in vitro human cells, in vivo murine models, clinical tissue analysis, and Mendelian randomization with sensitivity analyses supporting causality.
Study Flags
Red Flags
- •Mouse models may not fully replicate human diabetic retinopathy
- •NMN rescue was partial, suggesting other pathways are involved
- •Human MR analysis used SNPs as proxies, not direct CHKA measurements
Surprising Findings
CHKA silencing didn’t just reduce leaks — it activated the Notch pathway, which normally suppresses blood vessel growth, and this was reversed by NAD+ restoration.
Most therapies try to block angiogenesis directly (like anti-VEGF drugs), but here, blocking CHKA indirectly turns on a natural 'brake' on vessel growth — a completely different mechanism.
Practical Takeaways
If you have diabetes, ask your eye doctor about future CHKA biomarker tests — this enzyme could soon help predict who’s at highest risk for vision loss.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Human Case-Control
Subject
Moderate probability
on the GRADE evidence scale
This study found that a protein called CHKA is more active in the blood vessels of diabetic mice and some people with severe eye disease. It shows that when CHKA is turned down, the blood vessels get better—but this doesn't prove CHKA causes the problem in humans, just that they're linked.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Comprehensive single-cell RNA sequencing with robust bioinformatic analysis
- Multiple lines of experimental validation (genetic knockdown, pharmacological inhibition, metabolomics, transcriptomics)
- Use of both in vitro and in vivo models to confirm findings
Weaknesses
- No randomization or blinding in animal or human experiments
- Extremely small sample size in key functional experiments (n=6)
- Human clinical data limited to one cohort with no replication cohort
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists did a lot of smart experiments in mice and looked at human tissue, which is great. But they only tested a few mice and a few people, and didn't randomly assign treatments—so we can't be super sure the results will work for everyone. It's a good clue, but not a final answer.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
32 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=6)+0.6/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
This design cannot establish causation — the findings describe an association, not a cause. This study is primarily based on animal models and in vitro experiments with a very small human sample size (n=6 for diabetic mice in key experiments), lacks randomization, and uses observational clinical data. While Mendelian randomization suggests a possible causal link, the core experimental design does not meet criteria for establishing direct causation in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the provided text, and no industry affiliations or financial ties were identified among authors.
The study appears methodologically rigorous with single-cell RNA sequencing, in vivo validation, and clinical/genetic correlation. However, absence of a declared funding statement or COI section limits full transparency assessment. No evidence of industry influence or author conflicts was found.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Doctor Alex cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
12 researchersIf this is your work, this is how we attribute it on Fit Body Science. Ling Ren is listed as the lead author.